All In Biotech

BLA 125504 · Novartis Pharms Corp

Cosentyx

Secukinumab · Injection · Interleukin-17A Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 21, 2015

Approved uses

16

Original approval plus efficacy supplements

Registered trials

207

101 Phase 3, 16 recruiting

FAERS reports

161,904

65,379 serious, 9,022 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 15, 2026.

COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. ( 1.2 ) active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. ( 1.3 ) active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation. ( 1.4 ) active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. ( 1.5 ) moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older. ( 1.6 ) 1.1 Moderate to Severe Plaque Psoriasis COSENTYX ® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. 1.2 Active Psoriatic Arthritis COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. 1.3 Active Ankylosing Spondylitis COSENTYX is indicated for the treatment of active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. 1.4 Active Non-Radiographic Axial Spondyloarthritis COSENTYX is indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in adult patients with objective signs of inflammation. 1.5 Active Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. 1.6 Moderate to Severe Hidradenitis Suppurativa COSENTYX is indicated for...

Mechanism: Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the interleukin-17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Secukinumab inhibits the release of proinflammatory cytokines and chemokines.

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • COSENTYX · SECUKINUMAB 150MG/ML · INJECTABLE, INJECTION · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Secukinumab" as an intervention, any sponsor and status, largest first.

All 207 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective29,381
  • psoriasis22,918
  • pain16,854
  • arthralgia15,102
  • fatigue10,786
  • psoriatic arthropathy10,387
  • malaise9,598
  • pruritus9,542
  • rash9,297
  • condition aggravated8,697
  • diarrhoea8,168
  • nasopharyngitis7,955

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20121
20133
201411
20152,812
20166,260
201711,695
201820,874
201921,465
202022,595
202117,026
202217,155
202317,264
202411,057
20259,204
20264,482

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cosentyx (Secukinumab)

2024 spending

$1.1M

Beneficiaries

60

258 claims

Per beneficiary

$18,892

$418.27 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,133,519

Part B: Cosentyx (Secukinumab) · HCPCS J3247

2024 spending

$54.2M

Beneficiaries

3,236

12,224 claims

Per beneficiary

$16,757

2024 ASP limit $17.55 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$54,225,555

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 465 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.